Articles by Tyler Menichiello

31. Manufacturing CAR-T In Vivo 7/25/2024

    Manufacturing chimeric antigen receptor (CAR) T-cell therapies is a costly and complicated process. Interius BioTherapeutics is on a mission to reduce this complexity and get these therapies to patients faster — by manufacturing CAR T/NK cells in patients' bodies.

32. The Path To Producing An Insulin Biosimilar 7/17/2024

    I met with rBIO co-founder and president, Cameron Owen, as well as its CSO, Dr. Deenadayalan Bakthavatsalam, to learn about what it takes to develop an insulin biosimilar. They candidly told me about the company’s plan of execution, as well as how challenging it is to scale-up manufacturing to a commercial level (in the ballpark of several metric tons per year for insulin) — which is the company’s primary focus right now.

33. Inside Barinthus Biotherapeutics' Combination Immunotherapy Platform 6/28/2024

    In this Q&A with Barinthus Biotherapeutics' CEO, Bill Enright, he tells Bioprocess Online about the company's combination immunotherapy platform and its mission to develop a curative treatment for hepatitis B.

34. Improving AAV Purity Upstream With PCL Manufacturing 3/21/2024

    The downstream separation of AAV capsids affects end-product purity and has been identified as a key pain point of the industry. Ultragenyx’s Dennis Huang advises starting with higher-quality yields upstream.

35. The Industry's Positive Outlook For ADCs In 2024 2/26/2024

    Check out the results of DeciBio's Antibody-Drug Conjugates 2024 Industry Survey, which predict another bullish year for the growing modality.

36. Addressing The GMP Skills Shortage With Virtual Reality 2/14/2024

    In the U.K., a professor at the University of Birmingham is using virtual reality (VR) to help address the growing biomanufacturing skills shortage  — using virtual reality (VR).

37. Factors To Consider When Licensing An ADC Program 1/30/2024

    Elevation Oncology's CEO and CSO explain what made the company's lead ADC candidate, EO-3021, worth licensing from Chinese pharmaceutical company, CSPC.

38. 2023 ADC Roundup: A Year Of Collaboration And Licensing Deals 1/3/2024

    Despite the continuation of a poor funding climate in biotech, 2023 was a big year for antibody-drug conjugates (ADCs). 

39. RNA Vaccines: Just Scratching The Surface 12/28/2023

    RNA vaccines have shown promise in preventing infectious diseases and treating cancer, but clinical development varies markedly between the two. HDT Bio’s Dr. Berglund discusses this and how they can be improved.

40. How Creative Licensing Can Improve Patient Access 11/16/2023

    Members of Caring Cross and UC Berkeley's Innovative Genomics Institute and Office of IP And Industry Research Alliances discuss the important role technology transfer offices (TTOs) play in improving ATMP accessibility. TTOs can accomplish this by designing "strings-attached" research and licensing deals upstream in product development.